Key result
Tedisamil terminates atrial fibrillation at 100% efficacy in canine pacing and vagal models.
Why the study?
Tedisamil's efficacy in terminating atrial fibrillation had not been evaluated prior to this study.
Does tedisamil terminate atrial fibrillation in canine models?
Population
Two canine models of AF: 6 dogs with chronic fibrillatory pacing and 5 dogs with vagal stimulation
Comparison
Tedisamil intravenous doses of 0.1, 0.3, and 1 mg/kg vs no treatment
Design
Preclinical study using two canine AF models
Follow-up
30 minutes post-administration for reinduction assessment
Authors
Loading...
Tedisamil converts AF in two canine models; leaves open any role in human AF pending clinical trials.
Does tedisamil terminate atrial fibrillation in canine models?
The experimental antiarrhythmic drug tedisamil effectively and dose-dependently terminates atrial fibrillation and prevents its reinduction in canine models without causing ventricular arrhythmias.
Fischbach et al. (2001) studied Atrial fibrillation (canine models) (n=14). Tedisamil was evaluated on Termination of atrial fibrillation. Tedisamil 1 mg/kg intravenously was 100% effective in terminating atrial fibrillation in both chronic pacing and vagal stimulation canine models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: